on Seraxis, Inc.
Seraxis Secures $400,000 Maryland Stem Cell Research Fund Grant for Pancreatic Islet Replacement Therapy
GERMANTOWN, MD / ACCESSWIRE / June 14, 2024 / Seraxis, Inc. has been awarded a $400,000 grant from the Maryland Stem Cell Research Fund (MSCRF). This grant will support the characterization and efficacy testing of the preclinical SR-03 cell line as part of IND development. Seraxis aims to accelerate the validation and manufacturing of its SR-03 pancreatic cell line, which is engineered for universal allogenic transplant without requiring lifelong anti-rejection treatment.
CEO Dr. William Rust emphasized the significance of this funding in advancing Seraxis' goal of creating an immune-compatible allogenic pancreatic islet transplant for diabetic patients. Dr. Rust highlighted that over 1.4 million Americans with Type 1 Diabetes endure daily glucose monitoring and insulin administration to avoid complications. The SR-03 program builds on SR-02, an islet replacement therapy requiring immune suppression, set to enter clinical trials by late 2024 for hypoglycemic unawareness T1D patients.
Further details on Seraxis' SR-03 and SR-02 therapies will be available at the American Diabetes Association Annual Meeting in Orlando, June 21-24.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Seraxis, Inc. news